Up a level |
Slater, Kayleigh, Bosch, Rosa, Smith, Kaelin Francis, Jahangir, Chowdhury Arif, Garcia-Mulero, Sandra, Rahman, Arman, O'Connell, Fiona, Piulats, Josep M, O'Neill, Valerie, Horgan, Noel et al (show 5 more authors)
(2023)
1,4-dihydroxy quininib modulates the secretome of uveal melanoma tumour explants and a marker of oxidative phosphorylation in a metastatic xenograft model.
FRONTIERS IN MEDICINE, 9.
1036322-.
Carvajal, Richard D, Butler, Marcus O, Shoushtari, Alexander N, Hassel, Jessica C, Ikeguchi, Alexandra, Hernandez-Aya, Leonel, Nathan, Paul, Hamid, Omid, Piulats, Josep M, Rioth, Matthew et al (show 11 more authors)
(2022)
Clinical and molecular response to tebentafusp in previously treated patients with metastatic uveal melanoma: a phase 2 trial.
Nature Medicine, 28 (11).
2364-+.
Slater, Kayleigh, Heeran, Aisling B, Garcia-Mulero, Sandra, Kalirai, Helen ORCID: 0000-0002-4440-2576, Sanz-Pamplona, Rebeca, Rahman, Arman, Al-Attar, Nebras, Helmi, Mays, O'Connell, Fiona, Bosch, Rosa et al (show 8 more authors)
(2020)
High Cysteinyl Leukotriene Receptor 1 Expression Correlates with Poor Survival of Uveal Melanoma Patients and Cognate Antagonist Drugs Modulate the Growth, Cancer Secretome, and Metabolism of Uveal Melanoma Cells.
CANCERS, 12 (10).
E2950-.
Nathan, Paul, Hassel, Jessica C, Rutkowski, Piotr, Baurain, Jean-Francois, Butler, Marcus O, Schlaak, Max, Sullivan, Ryan J, Ochsenreither, Sebastian, Dummer, Reinhard, Kirkwood, John M et al (show 18 more authors)
(2021)
Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma.
NEW ENGLAND JOURNAL OF MEDICINE, 385 (13).
pp. 1196-1206.